J W Moul

Summary

Affiliation: Center for Prostate Disease Research
Country: USA

Publications

  1. ncbi request reprint Outcome research: prostate cancer databases
    Judd W Moul
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, MD 20852, USA
    Urol Oncol 7:39-42. 2002
  2. ncbi request reprint Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database
    Judd W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Urol Oncol 21:447-55. 2003
  3. ncbi request reprint Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003
    Judd W Moul
    Department of Defense Center for Prostate Cancer Research, Rockville, Maryland 20852, USA
    Urology 62:20-8. 2003
  4. ncbi request reprint Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
    Judd W Moul
    Department of Surgery, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda 20852, USA
    J Urol 171:1141-7. 2004
  5. ncbi request reprint Population screening for prostate cancer and emerging concepts for young men
    Judd W Moul
    Walter Reed Army Medical Center Washington, DC, USA
    Clin Prostate Cancer 2:87-97. 2003
  6. ncbi request reprint The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urol Clin North Am 28:459-72. 2001
  7. ncbi request reprint Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urology 57:174-7. 2001
  8. ncbi request reprint Molecular markers in prostate cancer: the role in preoperative staging
    Judd W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Clin Prostate Cancer 1:42-50. 2002
  9. ncbi request reprint Variables in predicting survival based on treating "PSA-only" relapse
    Judd W Moul
    Department of Surgery, Urology Service, Walter Reed Army Medical Center, Washington, DC, USA
    Urol Oncol 21:292-304. 2003
  10. ncbi request reprint Early prostate cancer: prevention, treatment modalities, and quality of life issues
    J W Moul
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, 1530 E Jefferson St, Rockville, MD 20852, USA
    Eur Urol 44:283-93. 2003

Collaborators

Detail Information

Publications97

  1. ncbi request reprint Outcome research: prostate cancer databases
    Judd W Moul
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, MD 20852, USA
    Urol Oncol 7:39-42. 2002
  2. ncbi request reprint Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database
    Judd W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Urol Oncol 21:447-55. 2003
    ..In a broad practice experience represented here, autologous blood donation would appear to be unnecessary for the majority of men and the blood loss advantage traditionally associated with perineal RP is no longer evident...
  3. ncbi request reprint Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003
    Judd W Moul
    Department of Defense Center for Prostate Cancer Research, Rockville, Maryland 20852, USA
    Urology 62:20-8. 2003
    ..Additional studies are needed, however, to define how to optimally use hormone therapy across various patient types...
  4. ncbi request reprint Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
    Judd W Moul
    Department of Surgery, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda 20852, USA
    J Urol 171:1141-7. 2004
    ....
  5. ncbi request reprint Population screening for prostate cancer and emerging concepts for young men
    Judd W Moul
    Walter Reed Army Medical Center Washington, DC, USA
    Clin Prostate Cancer 2:87-97. 2003
    ..In the future, a risk-stratified approach using molecular biomarkers and/or proteomics in young men is anticipated...
  6. ncbi request reprint The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urol Clin North Am 28:459-72. 2001
    ..In the long-term, multiple gene expression profiling of biopsy material using gene chips may revolutionize the care of patients with prostate cancer and those who elect radical prostatectomy...
  7. ncbi request reprint Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urology 57:174-7. 2001
    ..Certain chemopreventive agents may affect PSA physiology without affecting the disease process itself creating a meaningless epiphenomenon. Young black men may not generally be receptive to PSA testing or chemopreventive trials...
  8. ncbi request reprint Molecular markers in prostate cancer: the role in preoperative staging
    Judd W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Clin Prostate Cancer 1:42-50. 2002
    ..Still, this area holds great promise for improving the accuracy of staging and providing a more accurate prognosis of individual men with clinically localized prostate cancer...
  9. ncbi request reprint Variables in predicting survival based on treating "PSA-only" relapse
    Judd W Moul
    Department of Surgery, Urology Service, Walter Reed Army Medical Center, Washington, DC, USA
    Urol Oncol 21:292-304. 2003
    ..Early work would suggest that timing of recurrence, Gleason grade, and PSA velocity or doubling time during relapse are important prognostic factors. New data on PSA doubling time will be presented...
  10. ncbi request reprint Early prostate cancer: prevention, treatment modalities, and quality of life issues
    J W Moul
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, 1530 E Jefferson St, Rockville, MD 20852, USA
    Eur Urol 44:283-93. 2003
    ..The impact of therapeutic modality on QoL has become better characterized, as QoL instruments have been developed, validated and applied...
  11. ncbi request reprint Combination hormonal therapy: a reassessment within advanced prostate cancer
    J W Moul
    Center for Prostate Disease Research, Rockville, Maryland 20852 1532, USA
    Prostate Cancer Prostatic Dis 7:S2-7. 2004
    ..Further data are awaited to optimise the use of combination hormonal therapy in these new settings...
  12. ncbi request reprint Screening for prostate cancer in African Americans
    J W Moul
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, MD 20852, USA
    Curr Urol Rep 1:57-64. 2000
    ....
  13. ncbi request reprint Quantitative expression profile of PSGR in prostate cancer
    L L Xu
    Center for Prostate Disease Research CPDR, Department of Surgery, Uniformed Services University of the Health Sciences, Rockville, MD 20852, USA
    Prostate Cancer Prostatic Dis 9:56-61. 2006
    ..Strikingly high-percentage CaP cells overexpress PSGR warrants further studies of PSGR expression alterations to define subsets of CaPs...
  14. ncbi request reprint Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma
    E L Paquette
    Center for Prostate Disease Research, Rockville, Maryland 20852, USA
    Cancer 92:2673-9. 2001
    ..It appears reasonable to recommend PSA testing in AA men, who have historically experienced poor outcomes from prostate carcinoma...
  15. ncbi request reprint Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes
    L L Xu
    Center for Prostate Disease Research (CPDR, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Int J Cancer 92:322-8. 2001
    ..The discovery of new prostate-specific genes and ARGs provides a unique opportunity to determine the role of these genes in prostate cell growth, differentiation and tumorigenesis...
  16. pmc PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer
    V Srikantan
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799, USA
    Proc Natl Acad Sci U S A 97:12216-21. 2000
    ....
  17. ncbi request reprint CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
    M C Bettencourt
    Department of Surgery, Walter Reed Army Medical Center, Armed Forces Institute of Pathology, Washington, DC, USA
    J Urol 160:459-65. 1998
    ....
  18. pmc The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases
    D M Moreira
    Division of Urologic Surgery, Department of Surgery, and Duke Prostate Center, Duke University School of Medicine, Durham, NC, USA
    Prostate Cancer Prostatic Dis 13:87-93. 2010
    ..This indicates that currently used predictive models have similar performances among CM and AAM. Therefore, nomograms represent a valid and accurate method to predict BCR regardless of race...
  19. ncbi request reprint Investigating 3D tumor distribution for optimized diagnosis of prostate cancer
    J Zeng
    Department of Radiology, Georgetown University Medical Center, Washington, DC 20007, USA
    Stud Health Technol Inform 70:392-8. 2000
    ..By calculating cancer appearance inside each of these zones using a large number of prostate samples, we get the overall distributions of prostate cancers based on which an optimal biopsy protocol can be developed...
  20. ncbi request reprint External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence
    R A Petroski
    Center for Prostate Disease Research CPDR, Rockville, Maryland, USA
    Prostate Cancer Prostatic Dis 7:170-7. 2004
    ..To characterize the effectiveness and treatment morbidity a retrospective review was performed...
  21. ncbi request reprint Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients
    A S Merseburger
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urology 58:729-34. 2001
    ..CONCLUSIONS: Creatinine did not provide independent information for predicting pathologic stage or disease recurrence in patients with early prostate cancer...
  22. ncbi request reprint p53 regulates the expression of the tumor suppressor gene maspin
    Z Zou
    Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    J Biol Chem 275:6051-4. 2000
    ....
  23. doi request reprint Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy
    F R Schroeck
    Division of Urology, Department of Surgery, Duke Prostate Center DPC, Duke University Medical Center, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 11:371-6. 2008
    ..75. Race and prostate weight were independent predictors for BCR after RP. By incorporating these variables, we developed a nomogram, which provides a highly accurate means for estimating risk of BCR after RP...
  24. ncbi request reprint Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center
    S G Koff
    Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Prostate Cancer Prostatic Dis 5:152-8. 2002
    ..Clinical stage, pretreatment alkaline phosphatase and PSA nadir can be used to predict response for those men presenting with metastatic prostate cancer...
  25. ncbi request reprint Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    J Urol 166:1322-7. 2001
    ....
  26. doi request reprint African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center
    M Tsivian
    Division of Urology, Department of Surgery, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 16:91-4. 2013
    ..To investigate racial differences in tumor burden (cancer volume, cancer percentage and cancer to PSA ratios) in a large cohort of men undergoing radical prostatectomy (RP)...
  27. doi request reprint Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction
    M Kimura
    Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Andrology 1:256-61. 2013
    ..This study may help clinicians to discuss SB with patients and assess their potential for SB recovery following RP...
  28. ncbi request reprint p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein
    G L Griewe
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, 6825 Georgia Ave, NW, Washington, District of Columbia, USA
    Prostate Cancer Prostatic Dis 6:281-5. 2003
    ..The goal of this study was to evaluate p53 gene mutations in focal regions of primary prostate cancers positive by p53 immunostaining...
  29. ncbi request reprint PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer
    L L Xu
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 4799, USA
    Cancer Res 60:6568-72. 2000
    ....
  30. ncbi request reprint A novel human cancer culture model for the study of prostate cancer
    Y Yasunaga
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, MD 20814, USA
    Oncogene 20:8036-41. 2001
    ..This is the first documented case of an established human prostate cancer cell line from a primary tumor of a prostate cancer patient with telomerase...
  31. ncbi request reprint A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group
    R S Lance
    Department of Surgery, Urology Service, Madigan Army Medical Center, Tacoma, Washington, DC 98431-1100, USA
    BJU Int 87:61-5. 2001
    ..9%) than in the RRP group (none, P < 0.05). CONCLUSIONS: In similar populations of patients, RPP offers equivalent organ-confined, margin-positive and biochemical recurrence rates to RRP, while causing significantly less blood loss...
  32. ncbi request reprint Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Eur Urol 35:399-407. 1999
    ..More research is needed to assess new biomarkers and, most importantly, to standardize the methodology for sampling and assaying biomarkers in heterogeneous and multifocal prostate cancer...
  33. doi request reprint Predicting non-organ-confined prostate cancer in men diagnosed after 2000
    A A Caire
    Division of Urology, Department of Surgery, Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 13:248-51. 2010
    ..Preoperative information on disease stage may aid in treatment decisions and surgical approach...
  34. doi request reprint Predictive value of digital rectal examination for prostate cancer detection is modified by obesity
    D I Chu
    Division of Urologic Surgery and Duke Prostate Center, Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 14:346-53. 2011
    ..081). In conclusion, the predictive value of DRE is dependent on obesity and is significantly higher among obese men than normal-weight men...
  35. ncbi request reprint Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients
    A Desai
    Center for Prostate Disease Research CPDR, Rockville, MD 20852, USA
    Prostate Cancer Prostatic Dis 5:212-8. 2002
    ..Close step-sectioning provides better assurance of organ-confined disease, resulting in enhanced prediction of outcome by pathological (TNM) stage...
  36. ncbi request reprint Epidemiology and screening for prostate cancer
    J W Moul
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Am J Manag Care 3:1200-5; quiz 1208, 1210. 1997
    ..This activity is designed for primary care physicians, internists, and general audiences...
  37. pmc Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?
    S B Stewart
    Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 15:380-5. 2012
    ..The majority of these analyses are based on chemoprevention starting in men aged 50-55 years. We sought to evaluate the impact of varying both age at commencement of therapy and length of therapy on the cost-effectiveness of finasteride...
  38. ncbi request reprint Managing advanced prostate cancer with Viadur (leuprolide acetate implant)
    J W Moul
    Department of Defense Center for Prostate Disease Research, Uniformed Services University, Rockville, MD, USA
    Urol Nurs 21:385-8, 393-4; quiz 395-6. 2001
    ..Viadur is one aspect of a comprehensive approach to patient management, which also includes regular followup for prostate-specific antigen testing, digital rectal examination, and other tests throughout the 1-year therapy...
  39. doi request reprint Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database
    S J Freedland
    Department of Surgery, Duke University School of Medicine, Veterans Affairs Medical Center, Durham, NC 27710, USA
    Prostate Cancer Prostatic Dis 12:259-63. 2009
    ..In this study, obese men undergoing radical prostatectomy had higher-grade and larger tumors, providing further evidence that obese men undergoing radical prostatectomy have more aggressive prostate cancers...
  40. ncbi request reprint Investigating the distribution of prostate cancer using three-dimensional computer simulation
    M B Opell
    Department of Urology, Georgetown University Hospital, Washington, DC, USA
    Prostate Cancer Prostatic Dis 5:204-8. 2002
    ..Through an analysis of the spatial distribution of prostate cancer, we believe that new optimal biopsy strategies and techniques can be developed...
  41. ncbi request reprint Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors
    A Heidenreich
    Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    J Urol 159:1725-30. 1998
    ..The aim of our study was to examine TGCT and testicular cancer cell lines for deletions and mutations of the p15 and p16 genes...
  42. ncbi request reprint A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate
    L L Xu
    Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, Maryland, 20814 4799, USA
    Genomics 66:257-63. 2000
    ..PMEPA1, along with other highly androgen-induced prostate-specific genes, has potential to serve as an androgen signaling read-out biomarker in prostate tissue...
  43. ncbi request reprint The development of erectile dysfunction in men treated for prostate cancer
    T Siegel
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, USA
    J Urol 165:430-5. 2001
    ..CONCLUSIONS: Erectile dysfunction develops in greater than 80% of patients treated for prostate cancer. External beam radiation has the same risk for erectile dysfunction as radical prostatectomy...
  44. ncbi request reprint Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers
    J P Gaddipati
    Urology Service, Walter Reed Army Medical Center, Washington, DC 20307 5001
    Cancer Res 54:2861-4. 1994
    ..The stimulatory effect of these therapeutic agents on the codon 877 mutant AR further suggests that this frequently observed AR mutation may contribute to the treatment refractory disease...
  45. ncbi request reprint Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the re
    Michael S Cookson
    Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Urol 177:540-5. 2007
    ....
  46. ncbi request reprint Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure
    Alexandra J Stewart
    Brigham and Women s Hospital, Dana Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 23:6556-60. 2005
    ..2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM)...
  47. ncbi request reprint Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    Ping Zhou
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 23:6992-8. 2005
    ..We evaluated predictors of prostate cancer-specific mortality (PCSM) after prostate-specific antigen (PSA) failure after radical prostatectomy (RP) or radiation therapy (RT)...
  48. ncbi request reprint Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer
    Stephen A Brassell
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Urology 66:1229-33. 2005
    ..We also compared all PSAD derivatives to determine consistency...
  49. ncbi request reprint Rising prostate-specific antigen after primary prostate cancer therapy
    John F Ward
    Nevada Cancer Institute, Las Vegas, Nevada, USA
    Nat Clin Pract Urol 2:174-82. 2005
    ..Data from animal models provide a rationale for the use of these therapies, but there is a lack of evidence to support prolongation of progression-free survival or cancer-specific survival...
  50. doi request reprint Prostate-specific antigen screening among young men in the United States
    Charles D Scales
    Duke Prostate Center, Division of Urology, Department of Surgery, Duke University School of Medicine, Durham, North Carolina 27710, USA
    Cancer 113:1315-23. 2008
    ..Little is known about the use of PSA testing in these men. To understand policy implications of risk stratification, the authors sought to characterize PSA use among young men...
  51. ncbi request reprint Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years
    Leon Sun
    Division of Urology and Duke Prostate Center, Department of Surgery, Duke University Medical, Center, Durham, NC, USA
    BJU Int 99:753-7. 2007
    ..To identify threshold values of prostate-specific antigen (PSA) levels and PSA velocity (PSAV) to optimize the assessment of the risk of prostate cancer in young men, as prostate cancer is detected increasingly in men aged <50 years...
  52. ncbi request reprint Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience
    Vladimir Mouraviev
    Duke Prostate Center and Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Urology 69:311-4. 2007
    ....
  53. doi request reprint Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases
    Stephen J Freedland
    Urology Section, Department of Surgery, Veterans Affairs Medical Center, Duke University Medical Center, Durham, NC 27710, USA
    BJU Int 102:969-74. 2008
    ....
  54. doi request reprint Percent tumor involvement and risk of biochemical progression after radical prostatectomy
    Edward N Rampersaud
    Division of Urologic Surgery, Duke Prostate Center, Durham, North Carolina, USA
    J Urol 180:571-6; discussion 576. 2008
    ..We hypothesized percent tumor involvement may be a good correlate of outcome in all stages of prostate cancer...
  55. doi request reprint Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy
    Thomas J Polascik
    Duke Prostate Center and Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Prostate 68:1380-6. 2008
    ..We evaluated trends in pathologic staging among patients with localized PCa undergoing radical prostatectomy (RP), defining the frequency of unilateral cancers during 1988-1995, 1996-2000 and 2001-2006...
  56. doi request reprint Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy
    Florian R Schroeck
    Duke Prostate Center, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    BJU Int 102:28-32. 2008
    ..To compare the prostate-specific antigen (PSA) recurrence (PSAR) rates in patients undergoing robot-assisted laparoscopic radical prostatectomy (RALP) or radical retropubic prostatectomy (RRP)...
  57. ncbi request reprint Prostate cancer in the Baby Boomer generation: results from CaPSURE
    Charles D Scales
    Duke Prostate Center, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Urology 70:1162-7. 2007
    ..We sought to characterize prostate cancer (CaP) presentation among this group, and determine whether treatment patterns differ between Baby Boomers and the preceding generation...
  58. ncbi request reprint Rising PSA in nonmetastatic prostate cancer
    Judd W Moul
    Division of Urologic Surgery, Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA
    Oncology (Williston Park) 21:1436-45; discussion 1449, 1452, 1454. 2007
    ..In this article, we will explore these prostate cancer disease states with an emphasis on practical, clinically applicable approaches...
  59. ncbi request reprint Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens
    Darren E Whittemore
    Department of Pathology, Mike O Callaghan Federal Hospital, Nellis Air Force Base, Nevada, USA
    J Urol 179:516-22; discussion 522. 2008
    ..The Gleason grading system in reporting prostate cancer accounts for the primary and secondary Gleason pattern. The clinical significance of a higher tertiary (third most prevalent) grade is largely unrecognized...
  60. ncbi request reprint Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer
    Vladimir Mouraviev
    Duke Prostate Center and Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer 110:906-10. 2007
    ....
  61. ncbi request reprint Erectile function outcome reporting after clinically localized prostate cancer treatment
    Arthur L Burnett
    The Johns Hopkins Hospital, 600 North Wolfe St, Marburg 407, Baltimore, Maryland 21287 2411, USA
    J Urol 178:597-601. 2007
    ....
  62. ncbi request reprint Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality
    Jason A Efstathiou
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 68:342-7. 2006
    ..A PSA-DT of less than 3 months is a surrogate endpoint for PCSM...
  63. ncbi request reprint Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer 110:56-61. 2007
    ..Estimates of prostate cancer-specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with >or=1 high-risk factors...
  64. ncbi request reprint Guideline for the management of clinically localized prostate cancer: 2007 update
    Ian Thompson
    American Urological Association Education and Research, Inc
    J Urol 177:2106-31. 2007
  65. ncbi request reprint Prostate specific antigen recurrence after definitive therapy
    Stephen J Freedland
    Division of Surgery, Durham Veterans Affairs Medical Center, Durham, NC, USA
    J Urol 177:1985-91. 2007
    ..However, to do so the risks and benefits of the various options must be known. Therefore, we provide a comprehensive overview of the natural history and treatment options for men with prostate specific antigen-only recurrence...
  66. ncbi request reprint Treating the biochemical recurrence of prostate cancer after definitive primary therapy
    John F Ward
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Clin Prostate Cancer 4:38-44. 2005
    ..The potential opportunities for novel therapeutic agents with low associated morbidity are great...
  67. ncbi request reprint Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line
    Yongpeng Gu
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Anticancer Res 25:1-8. 2005
    ..NKX 3.1 and epithelial cell specific cytokeratin 8, androgen receptor (AR), prostate stem cell antigen and p16, but not PSA. AR protein was detected by Western blot analysis...
  68. ncbi request reprint Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms
    Kevin J Gancarczyk
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Urology 61:589-95. 2003
    ..To develop probability nomograms to predict pathologic outcome at the time of radical prostatectomy (RP) on the basis of established prognostic factors and prostate biopsy quantitative histology...
  69. ncbi request reprint Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Resea
    Peter A S Johnstone
    Investigation Department, Naval Medical Center, San Diego, CA 92134, USA
    Int J Radiat Oncol Biol Phys 55:964-9. 2003
    ..The records of the Department of Defense Center for Prostate Disease Research were queried for the biochemical disease-free results of patients after definitive RT and analyzed by age...
  70. ncbi request reprint p63 expression profile in normal and malignant prostate epithelial cells
    Leland D Davis
    Center for Prostate Disease Research CPDR, Department of Surgery, Uniformed Services University of the Health Sciences, 1530 East Jefferson Street, Rockville, MD 20852, USA
    Anticancer Res 22:3819-25. 2002
    ..The basal cell association underscores its critical functions in the biology of basal cells...
  71. ncbi request reprint PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium
    Bob Djavan
    Department of Urology, University of Vienna, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Eur Urol 43:12-27. 2003
    ..At last, the use of artificial neural networks will certainly enhance the selection of patients submitted to radical treatments as well as the selection of relapsing patients to allow a more appropriate adjuvant therapy...
  72. ncbi request reprint The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL
    Bill P Vanasupa
    Center for Prostate Disease Research, 1530 East Jefferson Street, Rockville, Maryland 20852, USA
    Urol Oncol 7:167-72. 2002
    ....
  73. ncbi request reprint Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues
    Axel S Merseburger
    Department of Genitourinary Pathology, Armed Forces Institute of Pathology AFIP, Washington, DC 20306 6000, USA
    Oncol Rep 10:223-8. 2003
    ..The TMA technique is probably more informative and reliable in evaluating the prognostic value of homogeneously expressed biomarkers...
  74. ncbi request reprint Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing
    Edmond L Paquette
    Center for Prostate Disease Research, Rockville, Maryland 20852, USA
    Urology 60:756-9. 2002
    ..To determine how the implementation of prostate-specific antigen (PSA) testing has affected disease-specific survival and other characteristics of prostate cancer...
  75. ncbi request reprint Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Researc
    Peter A S Johnstone
    Naval Medical Ctr, San Diego, Calif 92134 1014, USA
    Radiology 225:420-6. 2002
    ..To report on the first collaboration of the Department of Defense Center for Prostate Disease Research concerned with the relationship between African American race and biochemical disease-free outcomes after definitive radiation therapy...
  76. ncbi request reprint Screening for prostate cancer in high risk populations
    William J Catalona
    Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri, USA
    J Urol 168:1980-3; discussion 1983-4. 2002
    ..Consequently, screening at a younger age has been recommended for high risk men, however, there are limited data on actual screening results in young, high risk populations...
  77. ncbi request reprint Prostate-specific antigen as a marker of disease activity in prostate cancer
    Alan W Partin
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Oncology (Williston Park) 16:1218-24; discussion 1224, 1227-8 passim. 2002
    ..Part 2 of this two-part article, which began in the August issue, discusses the role of PSA in hormonal and drug therapies and in primary and secondary chemoprevention...
  78. ncbi request reprint Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database
    Judd W Moul
    Urology Service, Dept of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Surgery 132:213-9. 2002
    ....
  79. ncbi request reprint Prostate-specific antigen as a marker of disease activity in prostate cancer
    Alan W Partin
    Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287, USA
    Oncology (Williston Park) 16:1024-38, 1042; discussion 1042, 1047-8, 1051. 2002
    ..Part 1 of this two-part article, which concludes in the September issue, focuses on the physiology of PSA, its measurement and use in clinical practice, and its predictive value following radical prostatectomy and radiation therapy...
  80. ncbi request reprint Cadmium-induced neoplastic transformation of human prostate epithelial cells
    Keiichiro Nakamura
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Int J Oncol 20:543-7. 2002
    ..1 and cytokeratin 8 (CK8). These findings provide evidence of malignant transformation of human prostate epithelial cells exposed to this environmentally important chemical...
  81. ncbi request reprint Predictors of extracapsular extension and positive margins in African American and white men
    Edmond L Paquette
    Urology Service, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Urol Oncol 21:33-8. 2003
    ....
  82. ncbi request reprint Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy
    Jason C Massengill
    Department of Surgery, Center for Prostatic Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    J Urol 169:1670-5. 2003
    ..We rigorously tested pretreatment total testosterone levels as a potential staging and prognostic marker in a large cohort of 879 patients with localized cancer treated with radical prostatectomy...
  83. ncbi request reprint A novel neoplastic primary tumor-derived human prostate epithelial cell line
    Daejin Ko
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    Int J Oncol 22:1311-7. 2003
    ..This is the first documented case of a malignant AR and PSA positive established human prostate cancer cell line from a primary tumor of a prostate cancer patient...
  84. ncbi request reprint Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer
    John F Ward
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Curr Opin Urol 15:187-95. 2005
    ..Such prostate-specific antigen relapses, conservatively estimated to affect approximately 50 000 men each year, have become the most common form of advanced prostate cancer in the current period...
  85. ncbi request reprint Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer
    John F Ward
    Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Curr Opin Urol 15:181-6. 2005
    ..It also evaluates the array of diagnostic tests frequently employed when biochemical recurrence has occurred...
  86. ncbi request reprint Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome
    Gyorgy Petrovics
    Center for Prostate Disease Research CPDR, Department of Surgery and US Military Cancer Institute, Uniformed Services University, Rockville, MD 20852, USA
    Oncogene 24:3847-52. 2005
    ....
  87. ncbi request reprint Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy
    Judd W Moul
    Division of Urologic Surgery and Duke Prostate Cancer, Duke University, Durham, NC 27710, USA
    BJU Int 95:285-90. 2005
  88. ncbi request reprint A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes
    Yongpeng Gu
    Center for Prostate Disease Research, Department of Surgery, Uniformed Service University of Health Sciences, Bethesda, MD 20814, USA
    Int J Oncol 25:1057-64. 2004
    ..This is the first documented case of an AR and PSA expressing telomerase established human prostate cancer cell line with neoplastic phenotypes from a primary tumor of a prostate cancer patient...
  89. ncbi request reprint Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 96:509-15. 2004
    ....
  90. ncbi request reprint Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients
    Gyorgy Petrovics
    Department of Surgery, Center for Prostate Disease Research, US Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799, USA
    Oncogene 23:605-11. 2004
    ....
  91. ncbi request reprint Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy
    Christopher L Amling
    Department of Urology, Naval Medical Center, 34800 Bob Wilson Drive, San Diego, CA 92134 5000, USA
    J Clin Oncol 22:439-45. 2004
    ....
  92. ncbi request reprint Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy
    Al Baha Barqawi
    Division of Urology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Urology 62:872-6. 2003
    ..To evaluate the efficacy and tolerability of combined finasteride and low-dose flutamide for prostate-specific antigen (PSA)-only recurrence after definitive therapy and to determine the predictors of recurrence-free survival...
  93. ncbi request reprint Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era
    Corey A Carter
    Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
    J Clin Oncol 21:4001-8. 2003
    ..An analysis of the Department of Defense Center for Prostate Disease Research Database was undertaken to document younger men with low- or intermediate-grade PC who initially chose WW...
  94. ncbi request reprint Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Natl Cancer Inst 95:1376-83. 2003
    ..Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation therapy is a surrogate end point for prostate cancer-specific mortality by analyzing two multi-institutional databases...
  95. ncbi request reprint Biochemical recurrence of prostate cancer
    Judd W Moul
    Department of Surgery, Uniformed Services University of the Health Services, Bethesda, Maryland, USA
    Curr Probl Cancer 27:243-72. 2003
  96. ncbi request reprint Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients
    Chun Ling Gao
    Center for Prostate Disease Research, Department of Surgery, Uniformed Service University of the Health Science, Bethesda, Maryland 20814 4799, USA
    Clin Cancer Res 9:2545-50. 2003
    ....
  97. ncbi request reprint Prostate biopsy quantitative histology as a staging and prognostic factor
    Judd W Moul
    J Urol 167:526-7. 2002